Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda PAN

What Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda PAN does

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda PAN (IITD PAN / Hirszfeld Institute) is a Polish Academy of Sciences research institute established in 1952, headquartered at ul. Rudolfa Weigla 12, Wrocław, with approximately 82 staff. It conducts basic and applied research in immunology, experimental oncology, bacteriophage biology, vaccine development, microbiome science, genetics and epigenetics, and drug-carrier systems. Core scientific infrastructure includes the NeoLek Integrated Laboratory for Experimental Oncology and Innovative Technologies — Poland's only GLP-certified facility in this research profile (co-financed by the EU at 17.17 million PLN) — plus the Phage Therapy Unit (the only such unit in Poland integrated within a research institute) and the Polska Kolekcja Mikroorganizmów (PCM/BIOBANK) microorganism collection.

The institute's product and service portfolio comprises two peer-reviewed journals (Archivum Immunologiae et Therapiae Experimentalis, IF 3.9; Postępy Higieny i Medycyny Doświadczalnej, IF 0.3), fee-based Bioethics Committee opinions (1,000–10,000 PLN per opinion), preclinical GLP anticancer drug testing, phage therapy treatments, tissue immunology and SARS-CoV-2 diagnostics, the BINWIT scientific database, and the ApeFD facial database (published in Scientific Data, IF 6.9). It also runs Stacja IITD, the first science popularization project in the Polish Academy of Sciences, and MEDITRANSFER technology transfer.

Funding flows primarily from the Polish Academy of Sciences (PAN core budget) and competitive research grants from the National Science Centre (NCN), National Centre for Research and Development (NCBR), Medical Research Agency (ABM), and EU programs (e.g., the 17.17 million PLN NeoLek grant, 5.7 million PLN in NCN grants across five projects, 581,153 PLN from NCN OPUS 25). Commercial revenue is a minor supplement, generated through bioethics opinions, paid laboratory services, and Phage Therapy Unit treatments. Customers include Polish universities (Jagiellonian University, Medical University of Gdańsk, Warsaw University of Technology, Nicolaus Copernicus University), the Maria Skłodowska-Curie National Institute of Oncology, biotech firms (SyVento BioTech), and patient referrals for phage therapy.

Name

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda PAN

Legal name

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Website

https://hirszfeld.pl

Company type

Private

Founded year

1952

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), Central Laboratory Services (Core Lab Operations) (HLAGAEAA), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL)

Keywords

• Immunology research services
• Experimental oncology testing
• Bacteriophage therapy treatments
• GLP preclinical research
• Biological resource collection

Headquarters

HQ city

Wrocław

HQ country

Poland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Government funding (Polish Academy of Sciences): Core operational funding from the Polish Academy of Sciences (PAN), the national research institution
2. Research grants: Funding from National Science Centre (NCN), National Centre for Research and Development (NCBR), Medical Research Agency (ABM), and EU funding programs
3. Bioethics Committee opinions: Fee-based ethical review services for external research projects ranging from 1,000 to 10,000 PLN depending on review type
4. Research services and laboratory testing: Paid laboratory services including NeoLek laboratory services, PCM biological resource center services

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

IITD PAN is a publicly funded biomedical research institute conducting fundamental and applied research in immunology, experimental oncology, bacteriophage biology, vaccine development, and microbiome studies. It sells GLP-certified preclinical laboratory services through its NeoLek laboratory, operates the only integrated Phage Therapy Unit in Poland, maintains the Polish Microorganism Collection (PCM) biological resource center, provides diagnostic testing (tissue immunology, SARS-CoV-2), and publishes two scientific journals. Customers include pharmaceutical companies, other research institutions, hospitals, and individual patients requiring phage therapy.

Product overview

IITD PAN operates as a research institute of the Polish Academy of Sciences (established 1952) offering a portfolio of scientific journals, specialized research laboratories, medical services, and science communication initiatives. The core offerings include two peer-reviewed journals (Postępy Higieny i Medycyny Doświadczalnej with IF 0.3, and Archivum Immunologiae et Therapiae Experimentalis with IF 3.9), the NeoLek integrated GLP-certified laboratory for experimental oncology research, phage therapy medical services, diagnostic laboratories (tissue immunology, SARS-CoV-2), the Polska Kolekcja Mikroorganizmów (PCM/BIOBANK) biological resource center, and science popularization through the Stacja IITD project. Supporting infrastructure includes the BINWIT scientific information database and Meditransfer technology transfer center. Research areas span anticancer drug development, bacteriophage therapy, microbiome studies, and immunological research.

Differentiator

Problem solved

Functional benefit

Brands

• NeoLek: Integrated Laboratory for Experimental Oncology and Innovative Technologies - project focused on development of anticancer therapies with GLP-certified research capabilities
• Ośrodek Terapii Fagowej (Phage Therapy Unit)
• BIOBANK PCM (Polska Kolekcja Mikroorganizmów)
• MEDITRANSFER
• Stacja IITD
• Postępy Higieny i Medycyny Doświadczalnej
• Archivum Immunologiae et Therapiae Experimentalis

Products and services

• NeoLek – Integrated Laboratory for Experimental Oncology and Innovative Technologies
• Phage Therapy Unit (Ośrodek Terapii Fagowej)
• Polska Kolekcja Mikroorganizmów (PCM) / BIOBANK PCM
• Tissue Immunology Diagnostic Laboratory
• SARS-CoV-2 Infection Diagnostics Laboratory
• BINWIT – Scientific Information Database for Innovative Therapies
• Meditransfer – Technology Transfer Centre
• Bioethics Committee Opinion Services

Quantifiable outcome

• Archivum Immunologiae et Therapiae Experimentalis achieved Impact Factor 3.9, surpassing Journal of Immunology (3.4)
• +2 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Uniwersytet Mikołaja Kopernika w ToruniucoreStrategic or Co-development Partner · 1 January 2025Leader of NCN OPUS 25 project for ApeFD facial database research; collaboration with IITD's Department of Anthropology on perception studies (grant: 581,153 PLN for IITD).
• AWF WrocławminorStrategic or Co-development Partner · 1 January 2025Academy of Physical Education in Wrocław collaborated with IITD on ApeFD facial database project.
• Universidad de Las Palmas de Gran CanariaminorStrategic or Co-development Partner · 1 January 2025Spanish university partner in ApeFD facial database creation collaboration.
• Jagiellońskie Centrum Innowacji sp. z o.o.minorStrategic or Co-development Partner · 1 January 2025Innovation center representing Jagiellonian University in ADEVASCO project consortium.
• Łukasiewicz Research Network – PORTcoreStrategic or Co-development Partner · 1 January 2025Managing entity for PACMAN project on antibody-drug conjugates; strategic partner in Virtual Research Institute (WIB) initiatives.
• Uniwersytet Jagielloński (Jagiellonian University)coreStrategic or Co-development Partner · 3 December 2024Consortium partner in ADEVASCO project (Aptamer-Based Diagnosis of Endothelium in Vasculooncology) for personalized endothelial diagnostics in anticancer treatment. IITD's Laboratory of Experimental Anticancer Therapy led by Prof. Joanna Wietrzyk participates in this multi-institutional research initiative.
• Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – PIB w GliwicachcoreStrategic or Co-development Partner · 3 December 2024Maria Skłodowska-Curie National Institute of Oncology is a key consortium partner in the ADEVASCO vasculooncology project and co-organizer of immunotherapy conferences with IITD.
• Gdański Uniwersytet MedycznycoreStrategic or Co-development Partner · 3 December 2024Medical University of Gdańsk participates in the ADEVASCO consortium for vasculooncology research alongside IITD.
• Politechnika WarszawskacoreStrategic or Co-development Partner · 3 December 2024Warsaw University of Technology is a technical partner in the ADEVASCO consortium bringing engineering expertise to vasculooncology research collaboration.
• Instytut Rozrodu Zwierząt i Badań Żywności PAN w OlsztynieminorStrategic or Co-development Partner · 3 December 2024Partner in the ADEVASCO research consortium contributing to personalized endothelial diagnostics research.
• Uniwersytet Medyczny w WiedniuminorStrategic or Co-development Partner · 1 January 2024International collaboration partner in research on bacterial extracellular vesicles published in Journal of Extracellular Vesicles (IF 15.5).
• Uniwersytet AarhusminorStrategic or Co-development Partner · 1 January 2024European partner in bacterial extracellular vesicles research collaboration resulting in high-impact publication.
• Instytut KarolinskaminorStrategic or Co-development Partner · 1 January 2024International research collaborator on microbiome and extracellular vesicles studies published in Journal of Extracellular Vesicles.
• Uniwersytet Karola w PradzeminorStrategic or Co-development Partner · 1 January 2024Central European collaboration partner in microbiome research and bacterial vesicles studies.
• Czeska Akademia NaukminorStrategic or Co-development Partner · 1 January 2024Partner in microbiome research consortium studying bacterial extracellular vesicles.
• SyVento BioTechcoreStrategic or Co-development Partner · 1 January 2024Biotechnology company visit and collaboration for innovative personalized therapies; SyVento combines R&D with GMP manufacturing standards.

Scale indicators10 records

Expansion highlights5 records

Broad incumbents

• Karolinska Institutet: Swedish medical university and research institute partnering with IITD on microbiome/extracellular vesicle work; comparable in immunology research scope, doctoral training programs, and clinical/translational laboratory operations.
• Institut Pasteur: Larger, established European biomedical research institute with deep immunology, microbiology, and vaccinology programs; directly comparable as a public-sector immunology research organization with biological resource centers and translational pipelines.
• ATCC (American Type Culture Collection): Global biological resource center and culture collection; the closest commercial/institutional analogue to IITD's Polska Kolekcja Mikroorganizmów (PCM/BIOBANK) for standardized microorganism distribution.
• Charles River Laboratories: Global CRO with preclinical oncology and safety assessment services; comparable to IITD's NeoLek GLP-certified laboratory in preclinical anticancer drug testing, although operating at much larger commercial scale.
• Max Planck Institute for Infection Biology: Public German research institute focused on immunology and infectious disease; comparable in mission (basic immunology research, doctoral training, biological resource activities) and governance structure (public/governmental research institute).

Emerging players

• Adaptive Phage Therapeutics: US-based clinical-stage phage therapy company; comparable as a developer of phage-based therapeutics against antibiotic-resistant infections, an adjacent commercial counterpart to IITD's Phage Therapy Unit and pending phage purification IP.

Direct peers

• Eliava Institute of Bacteriophages, Microbiology and Virology: Georgian research institute dedicated to bacteriophage research and therapy; the most direct global comparator to IITD's Phage Therapy Unit, with similar focus on clinical phage therapy, phage purification, and biological resource functions.
• Maria Skłodowska-Curie National Institute of Oncology: Polish National Oncology Institute and IITD's ADEVASCO consortium partner; directly comparable in experimental oncology, anticancer therapy development, and clinical research collaboration with IITD PAN.
• Mossakowski Medical Research Institute PAS: Fellow Polish Academy of Sciences medical research institute in Warsaw; directly comparable in governance (PAS institute), funding model (Polish government + grants), research scope (experimental medicine), and doctoral training activities.
• Ludwik Hirszfeld Institute of Immunology and Experimental Therapy PAS: This is the subject company itself; included for completeness as the reference anchor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/iitdpan
• YouTubeyoutube.com/channel/UCClI04jb7L8WzojP4HSQZLg
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/instytut-immunologii-i-terapii-do%C5%9Bwiadczalnej-im-ludwika-hirszfelda-pan

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda PAN